Skip to main
CUR
CUR logo

Neuralstem (CUR)


$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy Neuralstem (CUR) Stock

About Neuralstem (CUR)

Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was foun...read more
Market cap
Today's volume
Revenue (TTM)
Avg. daily volume
EBITDA (TTM)-$11.45M
Open
Price / earnings ratio
Today's range
Debt / equity6.57x
52 week range
5 year debt / equity
Beta (LTM)
Interest coverage-1238.25x
Dividend & yield— (—)
Current ratio1.78x
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

How to buy Neuralstem stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in Neuralstem stock

    Navigate to the Explore page. Then, type Neuralstem into the search bar. When you see Neuralstem stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased Neuralstem stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Buy Neuralstem (CUR) Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.